Compare Ascendis Pharma A/S (ASND) vs Commvault Systems Inc (CVLT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Commvault Systems Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Commvault Systems Inc trades at $152.08 (market cap $6.24B). The key difference: Ascendis Pharma A/S is far larger — about 2.8× Commvault Systems Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Commvault Systems Inc nearer its low. Which is the better fit depends on your goals.
| ASND | CVLT | |
|---|---|---|
Market Cap | $17.74B | $6.24B |
Sector | Health | Technology |
52-Week High | $277.18 | $195.41 |
52-Week Low | $163.32 | $75.18 |
Enterprise Value | $18.11B | $6.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Commvault (CVLT) trades at $150.57, down 0.57% on the day, with a bullish technical signal from moving averages and strong support at $146. The company reported revenue of $995.62M in 2025, with net income of $76.11M, though earnings have been mixed with two beats and one miss in recent quarters. A high P/E of 95.3 indicates premium valuation, while ROE stands at 42.49%. Recent news highlights a securities class action lawsuit with a July 17, 2026 deadline.
Outlook is mixed: analyst consensus is bullish with 54.55% buy ratings and a $128.75 price target, but legal risks and high valuation pose headwinds. Revenue growth to $1.2B in 2026 offers upside, yet profit margin compression and lawsuit uncertainty require caution for investors seeking stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Commvault Systems Inc
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →
